We are live on ! Find out more
AYTU icon

AYTU BioPharma

39 hedge funds and large institutions have $9.81M invested in AYTU BioPharma in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

50% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 6

46% more capital invested

Capital invested by funds: $6.73M → $9.81M (+$3.07M)

18% more funds holding

Funds holding: 3339 (+6)

2.87% less ownership

Funds ownership: 39.88%37.02% (-2.9%)

Holders
39
Holders Change
+6
Holders Change %
+18.18%
% of All Funds
0.47%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
9
Reduced
6
Closed
3
Calls
Puts
Net Calls
Net Calls Change

AYTU Hedge Fund Activity: Q4 2025 in Review

39 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q4 2025, worth a combined $9.81M — up 46% from $6.73M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new AYTU positions and 3 closed out — a net gain of 6 holders — while 9 added to existing stakes and 6 trimmed.

The largest buyer was Two Sigma Investments, adding an estimated $86.1K. The largest seller was Stonepine Capital Management, cutting an estimated $175K.

  • 39 institutional investors held AYTU BioPharma (AYTU) as of Q4 2025, up from 33 in Q3 2025.
  • Funds reported $9.81M of AYTU BioPharma stock for Q4 2025, up 46% quarter-over-quarter.
  • 9 funds opened new AYTU BioPharma positions in Q4 2025 and 3 closed out, a net change of +6 holders.
  • The largest AYTU BioPharma buyer in Q4 2025 was Two Sigma Investments, an estimated $86.1K added.
  • The largest AYTU BioPharma seller in Q4 2025 was Stonepine Capital Management, an estimated $175K sold.

Based on aggregated 13F filings for Q4 2025.